A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

Exclusion Criteria

• •The participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. Participants with previous treatment of malignancy is eligible, provided that she has been disease free for \>3 years
• •The participant has a known sensitivity to docetaxel
• •The participant has a known sensitivity to agents of similar biologic composition as ramucirumab
• •The participant has a history of chronic diarrheal disease within 6 months prior to the study registration date
• •The participant has received irradiation to a major bone marrow area within 30 days prior to the study registration date
• •The participant has received any experimental agents within 4 weeks prior to the study registration date
• •The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
• •The participant has Grade 3-4 bleeding within 3 months prior to the study registration date
• •The participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy
• •The participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, or any other serious uncontrolled medical disorders
• •The participant has brain metastases
• •The participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness
• •The participant is pregnant or lactating
• •The participant has not fully recovered from effects of prior chemotherapy
• •The participant has undergone major surgery within 28 days prior to the study registration date